Omologazioni in worksharing del gruppo Access Consortium

Prodotti omologati da Swissmedic nell’ambito della New Active Substance Work Sharing Initiative (NASWSI) dell’Access Consortium:

Medicamento Principio attivo Autorità partner Link
Xofluza® Baloxavir Marboxil Australia’s Therapeutic Goods Administration (TGA), Health Canada Swissmedic omologa per la prima volta una nuova sostanza attiva (NAS) nell’ambito del Consorzio ACSS
Kesimpta® Ofatumumab Australia’s Therapeutic Goods Administration (TGA) , Health Canada, Health Sciences Authority (HSA) Singapore
Swissmedic ha omologato un nuovo medicamento nell’ambito dell’Access Consortium
VeraSeal® Fibrinogeno e Thrombina Australia’s Therapeutic Goods Administration (TGA), Health Canada  
Verquvo® Vericiguat Australia’s Therapeutic Goods Administration (TGA), Health Sciences Authority (HSA) Singapore
 
Kerendia® Finerenone Health Sciences Authority (HSA) Singapore, Australia’s Therapeutic Goods Administration (TGA)  
Nexviadyme® Avalglucosidase alfa Health Canada, Australia’s Therapeutic Goods Administration (TGA)  
Cibinqo® Abrocitinib Health Sciences Authority (HSA) Singapore  
Vabysmo® Faricimab Australia’s Therapeutic Goods Administration (TGA), Health Canada, Health Sciences Authority (HSA) Singapore, Medicines and Healthcare Products Regulatory Agency (MHRA) Collaborazione internazionale nel settore degli agenti terapeutici
Scemblix® Asciminib Australia’s Therapeutic Goods Administration (TGA), Health Canada, Health Sciences Authority (HSA) Singapore, Medicines and Healthcare Products Regulatory Agency (MHRA)  
Kapruvia® Difelikefalin Australia’s Therapeutic Goods Administration (TGA), Health Canada  
Mounjaro® Tirzepatid Australia’s Therapeutic Goods Administration (TGA), Health Canada, Health Sciences Authority (HAS) Singapore  
Tavneos® Avacopan Health Canada  
Vafseo® Vadadustat Australia’s Therapeutic Goods Administration (TGA), MHRA  
Alhemo® Concizumab Australia’s Therapeutic Goods Administration (TGA), Health Canada  

Prodotti omologati da Swissmedic nell’ambito della Generic Medicines Work Sharing Initiative (GMWSI) dell’Access Consortium:

Medicamento Principio attivo Autorità partner  Link
Everolimus Teva® Everolimus Australia’s Therapeutic Goods Administration (TGA), Health Canada  
Dabigatran Sandoz® Dabigatran Australia’s Therapeutic Goods Administration (TGA)  

Ultima modifica 14.12.2023

Inizio pagina